摘要
目的探讨子宫内膜癌组织中长链非编码RNA MALAT1的表达及临床意义。方法采用实时荧光定量聚合酶链反应（quantitative real-time polymerase chain reaction,qRT-PCR）方法检测榆林市神木县医院2009年9月至2010年9月确诊的104例子宫内膜癌患者新鲜子宫内膜癌组织标本及其对应的癌旁2 cm组织标本中MALAT1的表达,分析其与子宫内膜癌的临床病理特征关系以及诊断价值和预后关系。结果 MALAT1在子宫内膜癌组织中的表达明显高于子宫内膜癌旁组织（P〈0.05）;MALAT1在子宫内膜癌高、中分化组和低分化组中的阳性表达差异无统计学意义（P〉0.05）;MALAT1在子宫内膜癌组织中的表达与淋巴结转移、肿瘤浸润深度以及血管侵袭相关,差异均有统计学意义（P〈0.05）;ROC曲线AUC=0.7314（95%CI,0.6141~0.8487;P〈0.05）;MALAT1高表达和低表达组在总生存时间OS（χ2=7.269,P〈0.05）及无进展生存时间PFS（χ2=5.182,P〈0.05）上的差异有统计学意义。结论长链非编码RNA MALAT1在子宫内膜癌中是高表达的,可以作为子宫内膜癌的新型生物标记物和诊断靶标。
Objective To investigate the expression and clinical significance of long non -coding RNA （lncRNA） metastasis - associated lung adenocarcinoma transcript 1 （ MALAT1 ） in endometrial cancer. Methods 104 endometrial cancer tissue samples and 104 corresponding adjacent tissues were collected. Real -time quantitative polymerase chain reaction （qRT -PCR） was used to detect MALATI mRNA expression and its association with patient clinicopathological characteristics and overall survival of patients was further analyzed. A receiver operating characteristic （ROC） curve was constructed to determine the diagnostic value of MALAT1. Results MALAT1 expression was significantly upregulated in the endometrial cancer tissues compared with the matched adjacent tissues （ P 〈 0. 05 ） ; MALAT1 expression was no significant different in tumor differentiation （P 〉 0. 05 ） ;There was significant differences between lymph node metastasis, tumor infiltration level, vascular invasion in term of MALAT1 expression; the area under the ROC curve was 0. 7314 （95 % CI,0. 6141 -0. 8487 ;P 〈0. 05） ;The high MALAT1 expression and low expression groups are statistically significant in overall survival time （X2 = 7. 269, P 〈0. 05 ） and progression - free survival time （X2 = 5.182, P 〈 0. 05 ）. Conclusion LncRNA MALAT1 may be involved in carcinogenesis and may prove useful as a biomarker for diagnosis and prognostic significance in patients with endometrial cancer.
出处
《中国计划生育和妇产科》
2016年第6期51-55,共5页
Chinese Journal of Family Planning & Gynecotokology
